<PAGE> 1
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JULY 12, 1994
REGISTRATION NO. 33-52935
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------
AMENDMENT NO. 1
TO
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
------------------
AMERICAN CYANAMID COMPANY
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
MAINE
(STATE OR OTHER JURISDICTION OF
INCORPORATION OR ORGANIZATION)
ONE CYANAMID PLAZA
WAYNE, NEW JERSEY 07470
(201) 831-2000
(ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA CODE, OF
REGISTRANT'S PRINCIPAL EXECUTIVE OFFICES)
13-0430890
(I.R.S. EMPLOYER
IDENTIFICATION NO.)
JOSEPH S. MCAULIFFE
VICE PRESIDENT AND GENERAL COUNSEL
AMERICAN CYANAMID COMPANY
ONE CYANAMID PLAZA
WAYNE, NEW JERSEY 07470
(201) 831-2000
(NAME, ADDRESS, INCLUDING ZIP CODE,
AND TELEPHONE NUMBER, INCLUDING
AREA CODE, OF AGENT FOR SERVICE)
------------------
Copies to:
ANDREW B. JANSZKY
SHEARMAN & STERLING
599 LEXINGTON AVENUE
NEW YORK, NEW YORK 10022
(212) 848-4000
APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC:
From time to time after the effective date of this Registration Statement.
If the only securities being registered on this Form are being offered
pursuant to dividend or interest reinvestment plans, please check the following
box: / /
If any of the securities being registered on this Form are to be offered on
a delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, other than securities offered only in connection with dividend or interest
reinvestment plans, please check the following box: /X/
------------------
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR
DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL
FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION
STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(A) OF
THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME
EFFECTIVE ON SUCH DATE AS THE SECURITIES AND EXCHANGE COMMISSION, ACTING
PURSUANT TO SAID SECTION 8(A), MAY DETERMINE.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE> 2
INFORMATION CONTAINED HEREIN IS SUBJECT TO COMPLETION OR AMENDMENT. A
REGISTRATION STATEMENT RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION. THESE SECURITIES MAY NOT BE SOLD NOR
MAY OFFERS TO BUY BE ACCEPTED PRIOR TO THE TIME THE REGISTRATION STATEMENT
BECOMES EFFECTIVE. THIS PROSPECTUS SHALL NOT CONSTITUTE AN OFFER TO SELL OR
THE SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE
SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE
UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS
OF ANY SUCH STATE.
SUBJECT TO COMPLETION DATED JULY 12, 1994
PROSPECTUS
$600,000,000
AMERICAN CYANAMID COMPANY
DEBT SECURITIES
------------------------
American Cyanamid Company (the "Company") may offer from time to time one
or more series of its debt securities (the "Debt Securities") up to an aggregate
principal amount of $600,000,000 (or the equivalent in foreign denominated
currency or currency units). The Company will offer Debt Securities to the
public on terms determined by market conditions.
------------------------
The accompanying Prospectus Supplement sets forth the specific designation,
aggregate principal amount, purchase price, maturity, interest rate (or manner
of calculation thereof), time of payment of interest (if any), listing (if any)
on a securities exchange and any other specific terms of the Debt Securities.
------------------------
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES
AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE
SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED
UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE
CONTRARY IS A CRIMINAL OFFENSE.
------------------------
The Debt Securities may be offered directly, through agents designated from
time to time or through dealers or underwriters. If any agents of the Company or
any dealers or underwriters are involved in the offering of the Debt Securities
in respect of which this Prospectus is being delivered, the name of such agents,
dealers or underwriters and any applicable commissions or discounts will be set
forth in the Prospectus Supplement. The net proceeds to the Company from such
sale will also be set forth in the Prospectus Supplement.
The date of this Prospectus is July , 1994.
<PAGE> 3
AVAILABLE INFORMATION
The Company has filed with the Securities and Exchange Commission (the
"Commission") a Registration Statement on Form S-3 (the "Registration
Statement"), of which this Prospectus forms a part, covering the securities to
be sold pursuant to this Offering. As permitted by the rules and regulations of
the Commission, this Prospectus omits certain information, exhibits and
undertakings contained in the Registration Statement. Such additional
information, exhibits and undertakings can be inspected at and obtained from the
Commission as set forth below. For additional information with respect to the
Company, the Debt Securities and related matters and documents, reference is
made to the Registration Statement and the exhibits thereto. Statements
contained herein concerning any such document are not necessarily complete and,
in each instance, reference is made to the copy of such document incorporated by
reference in, or filed as an exhibit to, the Registration Statement. Each such
statement is qualified in its entirety by such reference.
The Company is subject to the informational reporting requirements of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), and
accordingly files reports, proxy statements and other information with the
Commission. Such reports, proxy statements and other information filed with the
Commission are available for inspection and copying at the public reference
facilities maintained by the Commission at Room 1024, 450 Fifth Street, N.W.,
Judiciary Plaza, Washington, D.C. 20549 and at certain regional offices of the
Commission located at Room 3190, Northwest Atrium Center, 500 West Madison
Street, Suite 1400, Chicago, Illinois 60661 and 7 World Trade Center, 13th
Floor, New York, New York 10048. Copies of such material can be obtained from
the Public Reference Section of the Commission, 450 Fifth Street, N.W.,
Judiciary Plaza, Washington, D.C. 20549 at prescribed rates. The Company's
Common Stock, par value $5.00 per share, is listed on the New York Stock
Exchange, and reports, proxy statements and other information concerning the
Company can be inspected at the New York Stock Exchange, 20 Broad Street, New
York, New York 10005.
THIS PROSPECTUS INCORPORATES DOCUMENTS BY REFERENCE WHICH ARE NOT PRESENTED
HEREIN OR DELIVERED HEREWITH. COPIES OF ANY SUCH DOCUMENTS, OTHER THAN EXHIBITS
TO SUCH DOCUMENTS WHICH ARE NOT SPECIFICALLY INCORPORATED BY REFERENCE HEREIN,
ARE AVAILABLE WITHOUT CHARGE TO ANY PERSON (INCLUDING ANY BENEFICIAL OWNER) TO
WHOM THE PROSPECTUS AND THE PROSPECTUS SUPPLEMENT IS DELIVERED UPON WRITTEN OR
ORAL REQUEST TO THE SECRETARY, AMERICAN CYANAMID COMPANY, ONE CYANAMID PLAZA,
WAYNE, NEW JERSEY 07470, TELEPHONE NUMBER (201) 831-2000.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The Company hereby incorporates by reference its (i) Annual Report on Form
10-K for the year ended December 31, 1993 and (ii) Quarterly Report on Form 10-Q
for the quarter ended March 31, 1994, which have been previously filed with the
Commission pursuant to the Exchange Act.
All documents filed by the Company pursuant to Sections 13(a), 13(c), 14
and 15(d) of the Exchange Act subsequent to the date hereof and prior to the
date upon which this offer is terminated, shall be deemed to be incorporated by
reference herein and to be part hereof from the date any such document is filed.
Any statements contained in a document incorporated or deemed to be
incorporated by reference herein shall be deemed to be modified or superseded
for purposes hereof to the extent that a statement contained herein (or in any
other subsequently filed document which also is incorporated by reference
herein) modifies or supersedes such statement. Any statement so modified or
superseded shall not be deemed to constitute a part hereof except as so modified
or superseded. All information appearing in this Prospectus is qualified in its
entirety by the information and financial statements (including notes thereto)
appearing in the documents incorporated herein by reference, except to the
extent set forth in this paragraph.
2
<PAGE> 4
THE COMPANY
The Company, organized in 1907 as a Maine corporation, is a research-based
life sciences company which, together with its subsidiaries, discovers and
develops medical and agricultural products and manufactures and markets them
throughout the world. The mailing address of the Company's principal executive
offices is One Cyanamid Plaza, Wayne, New Jersey 07470, and its telephone number
is (201) 831-2000.
The Company's medical products encompass LEDERLE branded and generic
pharmaceutical products; over-the-counter products including CENTRUM and other
multivitamins; LEDERLE-PRAXIS vaccines; DAVIS & GECK surgical sutures, wound
management devices and instruments for minimally invasive surgery; STORZ
ophthalmic, ear, nose and throat surgical devices, ophthalmic pharmaceuticals
and intraocular lenses; and ACUFEX arthroscopic instruments and equipment.
The Company's agricultural business encompasses herbicides, such as the
imidazolinone herbicides marketed as SCEPTER, PURSUIT, PURSUIT Plus and SQUADRON
for soybeans, PROWL (marketed as STOMP outside the United States) for soybeans,
cotton, corn, cereals, tobacco and vegetables, ARSENAL for vegetation control,
and ASSERT for wheat and barley; insecticides, such as COUNTER and THIMET and,
outside of North America, TORQUE, FASTAC, RIPCORD and CASCADE; fungicides
outside of North America, such as DELAN and ACROBAT; plant growth regulators,
such as CYCOCEL; animal feed supplements and health products, such as AUREOMYCIN
and, outside of the United States, AVOTAN, CYDECTIN and CYGRO; and animal
vaccines.
RECENT DEVELOPMENTS
On June 1, 1993, the Company and Immunex Corporation, a biopharmaceutical
company based in Seattle, Washington, created a new biopharmaceutical company by
merging the Company's North American Lederle oncology business with Immunex. The
Company also contributed $350 million in cash to the new company, which retained
the Immunex name. The Company received 53.5% of the common stock of the new
company.
In the fourth quarter of 1993, the Company acquired the crop protection
businesses outside of North America of the Royal-Dutch Shell Companies. The
acquisition included all of the Shell Companies' crop protection products; a
biosciences research center at Schwabenheim, Germany; a major formulations
facility in Genay, France; and other formulations sites around the world.
In the fourth quarter of 1993, the Company commenced a global, companywide
restructuring program, which is expected to be accomplished over three years.
The restructuring includes a reduction in the Company's work force, primarily in
the medical business, and other cost cutting measures designed to meet
increasingly competitive market conditions and government health care reform
efforts in the United States and Europe. The total work force reduction is
projected to be at least 2,500 positions and will take place over three years.
About one-half of the reduction will take place in the United States; the
balance will be overseas. The facilities affected include Pearl River, New York
and multiple locations overseas. The Company anticipates that efficiencies
related to the restructuring, primarily reduced labor and related benefits
costs, will be phased in over the next several years.
On July 8, 1994, the Company announced that it has agreed in principle to
sell its Davis & Geck wound management business to its European joint venture
partner, B. Braun Melsungen AG of Germany, for proceeds of approximately
$220,000,000, which include an intermediate term dividend-paying preferred stock
investment in the combined B. Braun and Davis & Geck business. The Company also
will enter into a multi-year manufacturing agreement with B. Braun and will
continue to own and operate its major suture plant in Manati, Puerto Rico. The
sale is subject to the finalization of definitive agreements and required
government approvals.
- ---------------
All brand names appearing in capital letters are trademarks, registered
trademarks or service marks owned by or licensed to the Company or its
subsidiaries.
3
<PAGE> 5
B. Braun is a privately held, research-based company, that develops and
manufactures specialty medical products for surgical and hospital use and
markets them throughout the world. The Company and B. Braun currently are
partners in joint venture wound management companies in Germany, Portugal and
Spain. Davis & Geck has operations in 60 countries, and had 1993 sales of
approximately $300,000,000.
RATIO OF EARNINGS TO FIXED CHARGES
The following table sets forth the ratio of earnings to fixed charges for
the Company for each of the years and periods indicated:
(In millions of dollars, except ratio amounts)
<TABLE>
<CAPTION>
THREE MONTHS YEAR ENDED DECEMBER 31,
ENDED -------------------------------------------------------
MARCH 31, 1994 1993 1992(1) 1991(1) 1990(1) 1989(1)
-------------- ------- ------- ------- ------- -------
<S> <C> <C> <C> <C> <C> <C>
Earnings(Loss)................ $176.0 $(34.2)(2) $628.9 $574.4 $478.9 (3) $554.8
=========== ======= ====== ====== ====== ======
Fixed Charges................. $ 20.5 $ 82.2 $ 77.9 $ 78.4 $114.4 $174.0
=========== ======= ====== ====== ====== ======
Ratio of Earnings to Fixed
Charges..................... 8.59 * 8.07 7.33 4.19 (3) 3.19
=========== ======= ====== ====== ====== ======
</TABLE>
- ---------------
* Calculation of the ratio results in an amount that is less than one. The
amount of earnings coverage deficiency for the fiscal year ended December
31, 1993 was $116.4.(2)
(1) Restated for discontinued operations related to the spin-off of Cytec
Industries Inc. in 1993.
(2) Includes one-time, pre-tax charges of $383.6 related to the acquisition of
Immunex Corporation and $207.9 related to a companywide restructuring
program. Excluding these charges, the ratio of earnings to fixed charges
would have been 6.78.
(3) Includes a pre-tax special charge of $97.2 associated primarily with the
curtailment and consolidation of certain product lines. Excluding this
charge, the ratio of earnings to fixed charges would have been 5.04.
For purposes of computing the ratio of earnings to fixed charges,
"earnings" consist of income from continuing operations (before taxes on
income), distributed income from associated companies and fixed charges
(excluding capitalized interest), and "fixed charges" consist of interest and
debt expense, capitalized interest and one-third of rental expense.
USE OF PROCEEDS
Except as otherwise described in the Prospectus Supplement, the Company
intends to use the net proceeds from the sale of the Debt Securities for general
corporate purposes, including, without limitation, working capital, capital
expenditures, stock purchase programs, repayment of indebtedness and
acquisitions. Funds not required immediately for such purposes may be invested
temporarily in short-term marketable securities.
DESCRIPTION OF DEBT SECURITIES
The Debt Securities will be unsecured and unsubordinated obligations of the
Company issued in one or more series under an indenture (the "Indenture")
between the Company and The Chase Manhattan Bank (National Association), as
trustee (the "Trustee"), the form of which is filed as an exhibit to the
Registration Statement of which this Prospectus is a part. The following
summaries of certain provisions of the Indenture do not purport to be complete
and are subject to, and are qualified in their entirety by reference to, all the
provisions of the Indenture. Wherever particular provisions of the Indenture or
terms defined therein are
4
<PAGE> 6
referred to herein or in the Prospectus Supplement, such provisions or terms are
incorporated by reference as a part of the statements made, and the statements
are qualified in their entirety by such reference. Section references are
references to sections of the Indenture. Capitalized terms not otherwise defined
herein have the meanings given to them in the Indenture.
The following description of the terms of the Debt Securities sets forth
certain general terms and provisions of the Debt Securities to which any
Prospectus Supplement may relate. The particular terms of the Debt Securities
offered by any Prospectus Supplement (the "Offered Debt Securities"), and the
extent, if any, to which such general provisions may apply to the Offered Debt
Securities, will be described in the Prospectus Supplement relating to such
Offered Debt Securities. The Indenture contains, among other things, the
following provisions.
GENERAL
The Indenture provides for the issuance of Debt Securities from time to
time, in one or more series. Reference is made to the Prospectus Supplement
which will describe the following terms of the Offered Debt Securities: (a) the
designation of the Offered Debt Securities; (b) any limit on the aggregate
principal amount of the Offered Debt Securities; (c) the date or dates on which
the Offered Debt Securities will mature; (d) the rate or rates (which may be
fixed or variable) per annum at which the Offered Debt Securities will bear
interest, if any, and the date from which such interest will accrue; (e) the
dates on which such interest, if any, will be payable and the Regular Record
Dates for such Interest Payment Dates; (f) whether the Offered Debt Securities
are exchangeable or convertible for or into new Debt Securities of a different
series or other securities (except shares of capital stock of the Company or any
subsidiary of the Company or securities directly or indirectly convertible into
or exchangeable for any such shares); (g) any sinking fund or purchase fund or
analogous obligation; (h) the period or periods within which or the date or
dates on which, the price or prices at which the Offered Debt Securities may be
redeemed at the option of the Company; (i) the place or places of payment of
principal of (and premium, if any) and interest on the Offered Debt Securities;
(j) whether the Offered Debt Securities are issuable as Registered Securities or
Bearer Securities or both; whether any such Debt Securities are to be issuable
initially in temporary global form; whether any such Debt Securities are to be
issuable in permanent global form with or without Coupons and, if so, whether
beneficial owners of interests in any such permanent global Debt Security may
exchange such interests for Debt Securities of like tenor of any authorized form
and denomination; whether Registered Securities may be exchanged for Bearer
Securities (if permitted by applicable laws and regulations); whether Bearer
Securities may be exchanged for Registered Securities; and the manner in which
the foregoing exchanges may be made; (k) any special provisions relating to the
issuance of any Bearer Securities of any series; (l) in the case of Offered Debt
Securities issued with an original issue discount, the principal amount thereof
payable upon acceleration of the maturity thereof; (m) the currency or
currencies or the currency units, if other than U.S. dollars, in which the
Offered Debt Securities are to be denominated or in which payments of principal,
and any premium and interest, may be payable; (n) if the principal (and premium,
if any) or interest, if any, on the Offered Debt Securities may be payable, in a
currency or currencies or units based on or related to currencies other than
that in which the Offered Debt Securities are stated to be payable, the period
or periods within which, and the terms and conditions upon which such election
may be made; (o) if the amount of payments of principal of (and premium, if any)
or interest, if any, on the Offered Debt Securities may be determined with
reference to an index based on a currency or currencies or units based on or
related to currencies other than that in which the Offered Debt Securities are
stated to be payable, the manner in which such amounts shall be determined; (p)
any deletions from, modifications of or additions to Events of Default or
covenants of the Company in the Indenture; (q) if the defeasance provisions of
the Indenture are not applicable to the Offered Debt Securities; and (r) any
other terms of the Offered Debt Securities. (Section 301)
The Debt Securities will be issuable as Registered Securities, as Bearer
Securities or both. Debt Securities of a series may be issuable in global form,
as described below under "Global Securities." (Section 301) Unless the
Prospectus Supplement relating thereto specifies otherwise, Registered
Securities denominated in U.S. dollars will be issued only in denominations of
$1,000 or any integral multiple thereof,
5
<PAGE> 7
and Bearer Securities denominated in U.S. dollars will be issued only in
denominations of $5,000 or any integral multiple thereof. (Section 302)
At the option of the Holder, Bearer Securities of any series will be
exchangeable for Registered Securities (if the Debt Securities of such series
are issuable in registered form) or Bearer Securities (if Bearer Securities of
such series are issuable in more than one denomination and such exchanges are
permitted by such series) of the same series, of any authorized denominations
and of any like tenor and aggregate principal amount, and Registered Securities
of any series (except a Book-Entry Security representing all or a portion of the
Debt Securities of such series) will be exchangeable for other Registered
Securities of the same series, of any authorized denominations and of any like
aggregate principal amount. If a Holder surrenders Bearer Securities in exchange
for Registered Securities between a Regular Record Date or, in certain
circumstances, a Special Record Date, and the relevant Interest Payment Date,
such Bearer Security will be surrendered without the coupon relating to such
Interest Payment Date. Registered Securities may not be exchanged for Bearer
Securities. (Section 305)
Unless otherwise indicated in a Prospectus Supplement, the covenants
contained in the Indenture and Debt Securities would not necessarily afford
holders of the Debt Securities protection in the event of a highly leveraged or
other transaction involving the Company that may adversely affect such holders.
GLOBAL SECURITIES
The Debt Securities may be issued in whole or in part in the form of one or
more Global Securities that will be deposited with, or on behalf of, the
Depository identified in the Prospectus Supplement. Global Securities may be
issued only in fully registered form and in either temporary or permanent form.
Unless and until it is exchanged in whole or in part for the individual Debt
Securities represented thereby, a Global Security may not be transferred except
as a whole by the Depository for such Global Security to a nominee of such
Depository or by a nominee of such Depository to such Depository or another
nominee of such Depository or by the Depository or any nominee of such
Depository to a successor Depository or any nominee of such successor.
The specific terms of any depository arrangement with respect to Debt
Securities issued in the form of one or more Global Securities will be described
in the Prospectus Supplement. Unless otherwise specified in the Prospectus
Supplement, the following provisions will apply to all depository arrangements.
Upon the issuance of a Global Security, the Depository for such Global
Security or its nominee will credit on its book-entry registration and transfer
system the respective principal amounts of the individual Debt Securities
represented by such Global Security to the accounts of institutions that have
accounts with such Depository ("Participants"). Such accounts shall be
designated by the underwriters, dealers or agents with respect to such Debt
Securities or by the Company if such Debt Securities are offered and sold
directly by the Company. Owners of beneficial interests in a Global Security
that are not Participants or persons that may hold through Participants but
desire to sell or otherwise transfer ownership of such beneficial interests by
book-entry on the records of the Depository may do so only through Participants
and persons that may hold through Participants. Because the Depository can only
act on behalf of Participants and persons that may hold through Participants,
the ability of an owner of a beneficial interest in a Global Security to pledge
such beneficial interests to persons or entities that do not participate in the
book-entry and transfer system of the Depository, or otherwise take actions in
respect of such beneficial interests, may be limited. The laws of some states
require that certain purchasers of securities take physical delivery of such
securities in definitive form. Such limitations on the ownership of beneficial
interests in a Global Security and such laws may impair the ability to transfer
beneficial interests in a Global Security.
So long as the Depository for a Global Security or its nominee is the
registered owner of such Global Security, such Depository or such nominee, as
the case may be, will be considered the sole owner or holder of the Debt
Securities represented by such Global Security for all purposes under the
Indenture. Except as provided below, owners of beneficial interests in a Global
Security will not be entitled to have any of the individual Debt Securities of
the series represented by such Global Security registered in their names, will
not
6
<PAGE> 8
receive or be entitled to receive physical delivery of any such Debt Securities
of such series in definitive form and will not be considered the owners or
holders thereof under the Indenture.
Payments of principal of (and premium, if any) and interest, if any, on
Debt Securities represented by a Global Security registered in the name of a
Depository or its nominee will be made to the Depository or its nominee, as the
case may be, as the registered owner of the Global Security representing such
Debt Securities. None of the Company, the Trustee, any paying agent or registrar
for such Debt Securities will have any responsibility or liability for any
aspect of the records relating to, or payments made on account of, beneficial
ownership interests in the Global Security for such Debt Securities or for
maintaining, supervising or reviewing any records relating to such beneficial
ownership interests.
The Company expects that the Depository for a series of Debt Securities or
its nominee, upon receipt of any payment of principal, premium or interest in
respect of a Global Security representing any of such Debt Securities,
immediately will credit Participants' accounts with payments in amounts
proportionate to their respective beneficial interests in the principal amount
of such Global Security as shown on the records of such Depository or its
nominee. The Company also expects that payments by Participants to owners of
beneficial interests in such Global Security held through such Participants will
be governed by standing instructions and customary practices, as is now the case
with securities held for the accounts of customers in bearer form or registered
in "street name". Such payments will be the responsibility of such Participants
and not of the Company or the Depository. Owners of beneficial interests in
Global Securities may experience some delay in the receipt of interest and
principal payments since the Depository for such Global Securities will forward
payments to its Participants, which in turn will forward them to persons that
hold beneficial interests in such Global Securities through such Participants.
If a Depository for a series of Debt Securities is at any time unwilling,
unable or ineligible to continue as depository and a successor depository is not
appointed by the Company within 90 days, the Company will issue individual Debt
Securities of such series in definitive form in exchange for the Global Security
representing such series of Debt Securities. In addition, the Company may at any
time and in its sole discretion, subject to any limitations described in the
Prospectus Supplement, determine not to have any Debt Securities of such series
represented by one or more Global Securities and, in such event, will issue
individual Debt Securities of such series in exchange for the Global Security or
Securities representing such series of Debt Securities. In either instance, the
Company will issue Debt Securities in definitive form, equal in aggregate
principal amount to the Global Securities, in such names and in such principal
amounts as the Depository for such Global Securities shall request.
COVENANTS
Under the terms of the Indenture, the Company will covenant and agree that
as long as any of the Debt Securities remain outstanding:
Payment of Principal and Interest. The Company will duly and punctually
pay the principal of (and premium, if any) and interest on each series of Debt
Securities in accordance with their terms and the Indenture. (Section 1001)
Maintenance of Office or Agency. The Company will maintain an office or
agency in each Place of Payment where Debt Securities may be presented or
surrendered for payment, where Debt Securities may be surrendered for transfer
or exchange and where notices and demands to or upon the Company in respect of
the Debt Securities and the Indenture may be served. (Section 1002)
Limitations on Liens. The Company will not, and will not permit any
Subsidiary to, secure indebtedness for money borrowed by incurring, creating or
assuming any Lien upon any Restricted Property, unless the Debt Securities then
outstanding are secured equally and ratably with such indebtedness, except for:
(i) any series of Debt Securities and any Lien existing on the date of the
issuance of such series; (ii) Liens existing on a corporation's property at the
time it first becomes a Subsidiary; (iii) Liens on a property existing at the
time acquired or incurred to secure the payment of all or part of the purchase
price thereof or to secure indebtedness incurred prior to, at the time of, or
within 12 months after, the acquisition of such property for
7
<PAGE> 9
the purpose of financing all or part of the purchase price thereof and any Lien
to secure indebtedness which is in excess of the purchase price (provided such
Liens are limited to such property and improvements thereon); (iv) certain
exploration, drilling, development, operation, construction and similar Liens
related to the property so affected; (v) Liens securing only indebtedness of a
Subsidiary owing to the Company or another Subsidiary; (vi) Liens securing any
industrial development, pollution control, or similar revenue bond; or (vii) any
extension, renewal or replacement of any of the foregoing Liens, provided the
principal amount of the indebtedness secured thereby shall not be increased.
(Section 1006)
Limitation on Sale and Leaseback Transactions. The Company will not enter
into any Sale and Leaseback Transaction, nor permit any Subsidiary owning
Restricted Property to do so, unless (i) the Company or such Subsidiary would be
entitled to have a lien placed on a Restricted Property to secure a Debt, in a
principal amount at least equal to the Attributable Debt in respect of such Sale
and Leaseback Transaction, without equally and ratably securing the Outstanding
Debt Securities without violating any provision of the above-mentioned
"Limitations on Liens" or (ii) the Company, within the six months immediately
following the effective date of such Sale and Leaseback Transaction, causes to
be applied to the acquisition of Restricted Property or to the retirement of
Debt Securities or Funded Debt an amount equal to the Attributable Debt in
respect of such Sale and Leaseback Transaction. (Section 1007)
Exempted Transactions. The limitations described above under "Limitations
on Liens" and "Limitation on Sale and Leaseback Transactions" will not apply to
a particular transaction if, thereafter, the sum of (a) the principal amount of
indebtedness secured by Liens the incurrence, creation or assumption of which
would otherwise require that the Company secure the Outstanding Debt Securities,
plus (b) the Attributable Debt in respect of certain Sale and Leaseback
Transactions, does not exceed 10% of the Consolidated Net Tangible Assets of the
Company and its consolidated subsidiaries. (Section 1008)
Waiver of Certain Covenants. With the consent of the holders of at least
66 2/3% in principal amount of the Debt Securities outstanding of any series,
the Company may, under certain circumstances, omit in respect of such series of
Debt Securities to comply with the covenants or conditions set forth under
"Limitations on Liens" and "Limitation on Sale and Leaseback Transactions".
(Section 1009)
CERTAIN DEFINITIONS
Certain terms defined in Section 101 of the Indenture are summarized below.
"Attributable Debt" means, as to any particular lease under which any
person is at the time liable, at any date as of which the amount thereof is to
be determined, the total net amount of rent (discounted from the respective due
dates thereof at the weighted average interest rate of Debt Securities of all
series (including the effective interest rate of any Original Issue Discount
Securities) which are Outstanding on the effective date of such transaction and
which have the benefit of "Limitation on Sale and Leaseback Transactions" above)
required to be paid by such person under such lease during the remaining term
thereof. The net amount of rent required to be paid under any such lease for any
such period shall be the total amount of the fixed rent payable by the lessee
with respect to such period, but shall exclude amounts required to be paid on
account of maintenance and repairs, insurance, taxes, assessments, water rates
and similar charges and any amount based upon or constituting a participation in
the revenues or earnings of any property. In the case of any lease which is
terminable by the lessee upon the payment of a penalty, such net amount shall
also include the amount of such penalty, but no rent shall be considered as
required to be paid under such lease subsequent to the first date upon which it
may be so terminated.
"Consolidated Net Tangible Assets" means, with respect to the Company, the
total amount of its assets (less applicable reserves and other properly
deductible items) after deducting therefrom (a) all current liabilities
(excluding the amount of liabilities which are by their terms extendable or
renewable at the option of the obligor to a date more than 12 months after the
date as of which the amount is being determined) and (b) all goodwill, trade
names, trademarks, patents, unamortized debt discount and expense and other like
intangibles.
8
<PAGE> 10
"Debt" means (i) all obligations represented by notes, bonds, debentures or
similar evidences of indebtedness; (ii) all indebtedness for borrowed money or
for the deferred purchase price of property or services other than, in the case
of such deferred purchase price, on normal trade terms; and (iii) all rental
obligations as lessee under leases which shall have been or should be, in
accordance with generally accepted accounting principles, recorded as capital
leases.
"Funded Debt" means Debt of the Company or a Subsidiary owning Restricted
Property maturing by its terms at, or extendable at the option of the obligor
to, a date more than 12 months from the date of determination.
"Lien" means any mortgage, lien, pledge, security interest or other
encumbrance (but not including any rights of set off arising by contract,
operation of law or otherwise).
"Restricted Property" means (a) any manufacturing facility, or portion
thereof, owned or leased by the Company or any Subsidiary and located within the
continental United States of America, other than (i) any such manufacturing
facility, or portion thereof, which, in the opinion of the Board of Directors,
is not of material importance to the business of the Company and its
subsidiaries taken as a whole, and (ii) any manufacturing facility, or portion
thereof, if its net book value is less than 2% of Consolidated Net Tangible
Assets, and (b) any shares of capital stock or indebtedness of any Subsidiary
owning any such manufacturing facility. As used in this definition,
"manufacturing facility" means property, plant and equipment used for actual
manufacturing and for activities directly related to manufacturing, and it
excludes sales offices, research facilities and facilities used only for
warehousing, distribution or general administration or any combination thereof.
"Sale and Leaseback Transaction" means any arrangement with any person
pursuant to which the Company or any Subsidiary leases any Restricted Property
that has been or is to be sold or transferred by the Company or the Subsidiary
to such person other than (a) temporary leases for a term, including renewals at
the option of the lease, of not more than three years, (b) leases between the
Company and a Subsidiary or between Subsidiaries, (c) leases of Restricted
Property executed by the time of, or within 12 months after the latest of, the
acquisition, the completion of construction or improvement or the commencement
of commercial operation of such Restricted Property, and (d) arrangements
pursuant to any provision of law with an effect similar to that under former
Section 168(f)(8)of the Internal Revenue Code of 1954.
"Subsidiary" means any corporation of which at least a majority of the
outstanding Voting Stock is owned, directly or indirectly, by the Company or one
or more Subsidiaries; provided that, for purposes of the Indenture, neither
Immunex Corporation nor Cytec Industries Inc. shall be a Subsidiary; and
provided further that, with respect to any corporation that is not a Subsidiary
on the date of the Indenture, but thereafter the Company or one or more of its
Subsidiaries acquires, directly or indirectly, at least a majority of the
outstanding Voting Stock of such corporation, the Board of Directors may
determine by resolution (which may be rescinded at any time) within 12 months
after such acquisition that such corporation shall not be a Subsidiary for
purposes of the Indenture.
EVENTS OF DEFAULT
As to any series of Debt Securities, an Event of Default is defined in the
Indenture as being any one of the following events and such other events as may
be established in the Debt Securities of such series: (a) failure to pay the
principal of or premium, if any, on any Debt Security of that series at its
Maturity; (b) failure to pay any interest on any Debt Security of that series
when due, continued for 30 days; (c) failure to deposit any sinking fund
payment, when due, in respect of any Debt Security of that series; (d) failure
to observe or perform any other of the covenants or agreements of the Company in
the Indenture, continued for 90 days after notice of such failure from the
Trustee or the holders of at least 25% in principal amount of the Outstanding
Debt Securities of that series; (e) a decree or order by a court of competent
jurisdiction adjudging the Company bankrupt or insolvent, or approving a
petition seeking reorganization of the Company or appointing a receiver,
liquidator or other similar official of the Company and such decree or order
continues in effect for 90 days; and (f) certain other events of bankruptcy,
insolvency or reorganization. (Section 501)
9
<PAGE> 11
The Indenture provides that (i) if an Event of Default described in clause
(a), (b), (c), (d) or (f) above (if the Event of Default under clause (d) or (f)
above is with respect to less than all series of Debt Securities then
outstanding) occurs and is continuing with respect to any series, either the
Trustee or the holders of not less than 25% in aggregate principal amount of the
Debt Securities of such series then outstanding (each such series acting as a
separate class) may declare the principal amount (or, if the Debt Securities of
such series are Original Issue Discount Securities, such portion of the
principal as may be specified in the terms of that series) of all Debt
Securities of such series and all accrued interest thereon to be due and payable
immediately; and (ii) if an Event of Default described in clause (d) or (f)
above (if the Event of Default under clause (d) or (f) above is with respect to
all series of Debt Securities then outstanding), or (e) above occurs and is
continuing, either the Trustee or the holders of not less than 25% in aggregate
principal amount of all the Debt Securities then outstanding (treated as one
class) may declare the principal amount (or, if any Debt Securities are Original
Issue Discount Securities, such portion of the principal amount as may be
specified in the terms thereof) of all the Debt Securities then outstanding and
all accrued interest thereon to be due and payable immediately, but upon certain
conditions such declarations may be annulled and past defaults (except for
defaults that remain uncured in the payment of principal of, any premium on, or
any interest on, such Debt Securities and in compliance with covenants) may be
waived by the holders of not less than a majority in aggregate principal amount
of the Debt Securities of such series then outstanding. (Sections 502 and 513)
The Indenture provides that, subject to the provisions of the Trust
Indenture Act of 1939, as amended, the Trustee will be under no obligation to
exercise any of its rights or powers under the Indenture if the Trustee has
reasonable grounds for believing that adequate indemnity is not reasonably
assured to it. Subject to such provisions for indemnification of the Trustee,
the holders of a majority in principal amount of the Outstanding Debt Securities
of any series will have the right to direct the time, method and place of
conducting any proceeding for any remedy available to the Trustee, or exercising
any trust or power conferred upon the Trustee under the Indenture, with respect
to the Debt Securities of that series.
The Company will be required to furnish to the Trustee annually a statement
as to the performance by the Company of certain of its obligations under the
Indenture and as to any default in such performance. (Section 1004)
CONSOLIDATION, MERGER, SALE OR CONVEYANCE
The Indenture provides that the Company may consolidate with, sell or
convey all or substantially all of its assets to, or merge into, any other
corporation, provided that, in any such case, (i) the successor corporation
shall be organized and existing under the laws of the United States of America
or a State thereof or the District of Columbia and shall expressly assume the
due and punctual payment of the principal of (and premium, if any) and interest
and sinking fund payments on all the Debt Securities, according to their tenor,
and the due and punctual performance and observance of all of the covenants and
conditions of the Indenture to be performed by the Company by supplemental
indenture satisfactory to the Trustee, executed and delivered to the Trustee by
such corporation, and (ii) such successor corporation shall not, immediately
after such merger or consolidation, or such sale or conveyance, be in default in
the performance of any such covenant or condition. (Section 801) In case of any
such consolidation, merger, conveyance or transfer, such successor will succeed
to and be substituted for the Company as obligor on the Debt Securities, with
the same effect as if it had been named in the Indenture as the Company.
(Section 802)
MODIFICATION OF THE INDENTURE
With certain exceptions, the Indenture or the rights of the holders of the
Debt Securities may be modified by the Company and the Trustee with the consent
of the holders of not less than 66 2/3% in aggregate principal amount of the
Debt Securities of each series affected by such modification then Outstanding,
but no such modification may be made without the consent of the holder of each
Outstanding Debt Security affected thereby which would (a) change the maturity
of any payment of principal of or any premium or any installment of interest on
any Debt Security, or reduce the principal amount thereof or the interest or any
premium thereon, or change the method of computing the amount of principal
thereof or interest thereon on
10
<PAGE> 12
any date or change any place of payment where, or the currency (or units based
on or related to currencies) in which, any Debt Security or any premium or
interest thereon is payable, or change the currency (or units based on or
related to currencies) in which any Debt Security is denominated, or impair the
right to institute suit for the enforcement of any such payment on or after the
maturity thereof (or, in the case of redemption or repayment, on or after the
redemption date or the repayment date, as the case may be); (b) reduce the
percentage in principal amount of the Outstanding Debt Securities of any series,
the consent of whose holders is required for any such modification, or the
consent of whose holders is required for any waiver of compliance with certain
provisions of the Indenture or certain defaults thereunder and their
consequences provided for in the Indenture; or (c) modify any of the provisions
of certain sections of the Indenture, including the provisions summarized in
this paragraph, except to increase any such percentage or to provide that
certain other provisions of the Indenture cannot be modified or waived without
the consent of the holder of each outstanding Debt Security affected thereby.
(Section 902)
DEFEASANCE OF DEBT SECURITIES AND CERTAIN COVENANTS AND CERTAIN EVENTS OF
DEFAULT
Unless otherwise indicated in the Prospectus Supplement, the Company, at
its option, (a) will be discharged from its obligations with respect to any
series of Debt Securities or (b) will cease to be under any obligation to comply
with certain restrictive covenants of the Indenture (as described under
"Limitations on Liens", "Limitation on Sale and Leaseback Transactions" and
"Exempted Transactions" and any other limitations applicable to the Debt
Securities that are determined pursuant to the Indenture to be subject to the
provision described in this paragraph), and certain Events of Default will cease
to be applicable, with respect to any series of Debt Securities, upon the
deposit with the Trustee, in trust, of money or the equivalent in non-callable
securities, or securities callable at the option of the holder thereof, of the
government which issued the currency in which the Debt Securities are
denominated or government agencies backed by the full faith and credit of such
government, or a combination thereof, which through the payment of interest
thereon and principal thereof in accordance with their terms, without
reinvestment thereof, will provide money in an amount sufficient to pay all the
principal (including mandatory sinking fund payments) and any premium of,
interest on and any repurchase obligations with respect to such series of
Outstanding Debt Securities and Coupons, if any, of such series on the dates
such payments are due in accordance with the terms of the Debt Securities. To
exercise any such option, no Event of Default or event which with notice or
lapse of time would become an Event of Default with respect to the Debt
Securities of such series shall have occurred and be continuing. The Company is
required to deliver to the Trustee an Opinion of Counsel to the effect that the
deposit and related defeasance would not cause the holders of the Debt
Securities to recognize income, gain or loss for federal income tax purposes
and, in the case of the Debt Securities being discharged, accompanied by a
ruling to such effect from the United States Internal Revenue Service. (Section
403)
THE TRUSTEE
The Chase Manhattan Bank (National Association) is the Trustee under the
Indenture. The Company maintains banking and other commercial relationships with
The Chase Manhattan Bank (National Association) and its affiliates in the
ordinary course of business.
PLAN OF DISTRIBUTION
The Company may offer and sell the Debt Securities being offered hereby to
or through agents, underwriters and dealers and to other purchasers directly or
through agents.
The Distribution of Debt Securities may be effected from time to time in
one or more transactions at a fixed price or prices, which may be changed, at
market prices prevailing at the time of sale, at prices related to such
prevailing market prices or at negotiated prices.
Offers to purchase Debt Securities may be solicited by agents designated by
the Company from time to time. Any such agent, who may be deemed to be an
underwriter, as that term is defined in the Securities Act of 1933, as amended
(the "Securities Act"), involved in the offer or sale of the Debt Securities in
respect of which this Prospectus is delivered will be named, and any commissions
payable by the Company to such agent set forth, in the Prospectus Supplement.
Unless otherwise indicated in the Prospectus Supplement, any such agent will be
acting on a best efforts basis for the period of its appointment. Agents may be
entitled under
11
<PAGE> 13
agreements which may be entered into with the Company to indemnification by the
Company against certain liabilities, including liabilities under the Securities
Act, and may be customers of, extend credit to, engage in transactions with or
perform services for the Company in the ordinary course of business.
If any underwriters are utilized in the sale of Debt Securities in respect
of which this Prospectus is delivered, the Company will enter into an
underwriting agreement with such underwriters at the time of sale to them and
the names of the underwriters and the terms of the transaction will be set forth
in the Prospectus Supplement, which will be used by the underwriters to make
resales of the Debt Securities in respect of which this Prospectus is delivered
to the public. The underwriters may be entitled, under the relevant underwriting
agreement, to indemnification by the Company against certain liabilities,
including liabilities under the Securities Act, and may be customers of, extend
credit to, engage in transactions with or perform services for the Company in
the ordinary course of business.
If a dealer is utilized in the sale of the Debt Securities in respect of
which this Prospectus is delivered, the Company will sell such Debt Securities
to the dealer, as principal. The dealer may then resell such Debt Securities to
the public at varying prices to be determined by such dealer at the time of
resale. Dealers may be entitled to indemnification by the Company against
certain liabilities, including liabilities under the Securities Act, and may be
customers of, extend credit to, engage in transactions with or perform services
for the Company in the ordinary course of business.
If so indicated in the Prospectus Supplement, the Company will authorize
agents, underwriters or dealers to solicit offers by certain purchasers to
purchase Debt Securities from the Company at the public offering price set forth
in the Prospectus Supplement pursuant to delayed delivery contracts providing
for payment and delivery on a specified date in the future. Such contracts will
be subject to only those conditions set forth in the Prospectus Supplement, and
the Prospectus Supplement will set forth the commission payable for solicitation
of such offers.
LEGAL OPINION
The legality of the Debt Securities to be issued is being passed upon for
the Company by Joseph S. McAuliffe, Esq., Vice President and General Counsel of
the Company and for the underwriters or agents by Shearman & Sterling. Mr.
McAuliffe owns 125 shares of Common Stock, has options to purchase 25,945
additional shares of Common Stock, of which 16,589 shares are currently
eligible, has rights to receive 706 shares of Common Stock upon retirement and
has 1,661 shares of Common Stock allocated to his account under the Company's
Savings Plan. Shearman & Sterling, from time to time, represents the Company in
certain matters.
EXPERTS
The consolidated financial statements and schedules of the Company and its
subsidiaries as of December 31, 1993 and 1992, and for each of the years in the
three-year period ended December 31, 1993, incorporated by reference herein have
been incorporated by reference herein in reliance upon the reports of KPMG Peat
Marwick, independent certified public accountants, incorporated by reference
herein, and upon the authority of said firm as experts in accounting and
auditing. The reports of KPMG Peat Marwick covering the December 31, 1993
financial statements and schedules refer to the adoption of the provisions of
Statements of Financial Accounting Standards No. 106, "Employers' Accounting for
Postretirement Benefits Other Than Pensions", and No. 109, "Accounting for
Income Taxes", effective January 1, 1993.
12
<PAGE> 14
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION
The estimated fees and expenses in connection with the issuance and
distribution of the Debt Securities registered hereunder are as follows:
<TABLE>
<S> <C>
Securities and Exchange Commission registration fee............... $206,898
Trustee's fees and expenses....................................... 8,200*
"Blue Sky" fees and expenses...................................... 17,500*
Printing and engraving fees and expenses.......................... 15,000*
Legal fees and expenses........................................... 5,000*
Accounting fees and expenses...................................... 25,000*
Rating Agency fees................................................ 135,000*
Miscellaneous..................................................... 5,000*
--------
Total................................................... $417,598*
========
</TABLE>
- ---------------
* Estimated
ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS
Article IV of the By-laws of the Company currently provides that, except as
limited by the following two sentences, the Company shall indemnify any natural
person who is made a party or threatened to be made a party to any action or
proceeding by reason of his serving as a director, officer or employee of the
Company (or serving at the request of the Company as a director, officer,
trustee, employee, partner, fiduciary or agent of another entity or employee
benefit plan) against expenses reasonably incurred by him in connection with
such action or proceeding. No indemnification is provided to any person with
respect to any matter as to which he has been finally adjudicated not to have
acted in good faith in the reasonable belief that his action was in the best
interests of the Company or, with respect to any criminal action, had reasonable
cause to believe that his conduct was unlawful. Furthermore, no indemnification
is provided to any natural person with respect to (i) any action or proceeding
(other than a successful action for indemnification) initiated by such person,
unless such action or proceeding was authorized by the Board of Directors of the
Company or (ii) any action or proceeding brought by (but not in the right of)
the Company or a subsidiary against such person, unless indemnification is
authorized in the particular case by the Board of Directors of the Company.
Expenses incurred in defending an action or proceeding may be advanced as
authorized by the Board of Directors of the Company upon receipt of an
undertaking from the indemnified person. The indemnification provisions of
Article IV of the By-laws of the Company are not exclusive.
Section 719 of the Maine Business Corporation Act (the "MBCA") provides
that a corporation has the power to, or if provided in the by-laws shall,
indemnify any person made or threatened to be made a party to a proceeding by
reason of his serving as a director, officer, employee or agent of the
corporation (or serving at the request of the corporation as a director,
officer, trustee, partner, fiduciary, employee or agent of another entity)
provided that no indemnification shall be made to any person finally adjudicated
to not have acted honestly or in the reasonable belief that his action was in
(or not opposed to) the best interests of the corporation, or in the case of a
criminal proceeding, had reasonable cause to believe that his conduct was
unlawful. In certain cases, expenses incurred in defending any proceeding may be
advanced by the corporation upon receipt of an undertaking by the indemnified
person. Unless required by a corporation's by-laws, such indemnification shall
be made only as authorized by the Board of Directors in the particular case. The
MBCA provides that notwithstanding the foregoing, a corporation may not
indemnify any person with respect to an action or proceeding asserted in the
right of the corporation as to which such person is finally adjudicated to be
liable, unless the court in which such action or proceeding was brought
determines that such person is fairly
II-1
<PAGE> 15
and reasonably entitled to indemnification. In the case where any person has
been successful in defending any action or proceeding described above, the
corporation shall provide indemnification to such person.
Section 719 of the MBCA provides that a corporation has the power to
purchase insurance on behalf of directors, officers and agents of the
corporation, whether or not the corporation would have the power to indemnify
such person.
Section 716 of the MBCA provides that a director shall not be held
personally liable for monetary damages for failure to discharge his duties as
such unless he is found not to have acted honestly or in the reasonable belief
that the action was in, or not opposed to, the best interests of the corporation
and its shareholders.
The Company carries directors' and officers' liability insurance that
covers liabilities and expenses of the Company's directors and officers.
ITEM 16. EXHIBITS
<TABLE>
<S> <C>
1.1 Form of Purchase Agreement*
4.1 Form of Indenture between American Cyanamid Company and The Chase Manhattan Bank
(National Association), as trustee*
5.1 Opinion of Joseph S. McAuliffe, Esq., as to the legality of the securities being
offered*
12.1 Statement of computation of Ratio of Earnings to Fixed Charges
23.1 Consent of KPMG Peat Marwick
23.2 Consent of Joseph S. McAuliffe, Esq. (included in Exhibit 5.1 hereto)*
24.1 Powers of Attorney*
25.1 Form T-1 Statement of Eligibility of Trustee under the Trust Indenture Act of
1939 of The Chase Manhattan Bank (National Association)*
</TABLE>
- ---------------
* Previously filed.
ITEM 17. UNDERTAKINGS
The undersigned Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being
made, a post-effective amendment to this Registration Statement:
(i) to include any prospectus required by Section 10(a)(3) of the
Securities Act of 1933 (the "Securities Act");
(ii) to reflect in the prospectus any facts or events arising after
the effective date of the Registration Statement (or the most recent
post-effective amendment thereof) which, individually or in the
aggregate, represent a fundamental change in the information set forth
in the Registration Statement;
(iii) to include any material information with respect to the plan
of distribution not previously disclosed in the Registration Statement
or any material change to such information in the Registration
Statement;
provided however, that paragraphs (1)(i) and (1)(ii) do not apply if the
registration statement is on Form S-3 and the information required to be
included in a post-effective amendment by those paragraphs is contained in
periodic reports filed by the Registrant pursuant to Section 13 or Section
15(d) of the Securities Exchange Act of 1934 (the "Exchange Act") that are
incorporated by reference in the registration statement.
II-2
<PAGE> 16
(2) That, for the purpose of determining any liability under the
Securities Act, each such post-effective amendment shall be deemed to be a
new registration statement relating to the securities offered therein, and
the offering of such securities at that time shall be deemed to be in the
initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the
termination of the offering.
The undersigned Registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act, each filing of the
Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the
Exchange Act (and, where applicable, each filing of an employee benefit plan's
annual report pursuant to Section 15(d) of the Exchange Act) that is
incorporated by reference in the Registration Statement shall be deemed to be a
new registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof.
Insofar as indemnification for liabilities arising under the Securities Act
may be permitted to directors, officers and controlling persons of the
Registrant pursuant to the foregoing provisions, or otherwise, the Registrant
has been advised that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in the Securities Act
and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the Registrant of expenses
incurred or paid by a director, officer or controlling person of the Registrant
in the successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being
registered, the Registrant will, unless in the opinion of its counsel the matter
has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public
policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue.
II-3
<PAGE> 17
SIGNATURES
PURSUANT TO THE REQUIREMENTS OF THE SECURITIES ACT OF 1933, AS AMENDED,
REGISTRANT CERTIFIES THAT IT HAS REASONABLE GROUNDS TO BELIEVE THAT IT MEETS ALL
THE REQUIREMENTS FOR FILING ON FORM S-3 AND HAS DULY CAUSED THIS REGISTRATION
STATEMENT OR AMENDMENT THERETO TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED,
THEREUNTO DULY AUTHORIZED IN WAYNE, NEW JERSEY, ON THE 12TH DAY OF JULY, 1994.
AMERICAN CYANAMID COMPANY
(Registrant)
By: A. J. COSTELLO
----------------------------------
A. J. COSTELLO
CHAIRMAN AND CHIEF EXECUTIVE OFFICER
PURSUANT TO THE REQUIREMENTS OF THE SECURITIES ACT OF 1933, AS AMENDED,
THIS REGISTRATION STATEMENT OR AMENDMENT THERETO HAS BEEN SIGNED BY THE
FOLLOWING PERSONS IN THE CAPACITIES INDICATED ON THE 12TH DAY OF JULY, 1994.
By: A. J. COSTELLO
----------------------------------
A. J. COSTELLO
CHAIRMAN AND CHIEF EXECUTIVE OFFICER
(PRINCIPAL EXECUTIVE OFFICER AND
DIRECTOR)
By: T. D. MARTIN
----------------------------------
T. D. MARTIN
VICE PRESIDENT
(PRINCIPAL FINANCIAL OFFICER)
<TABLE>
<CAPTION>
SIGNATURE TITLE DATE
--------- ----- ----
<S> <C> <C>
F. V. ATLEE* Director July 12, 1994
- ----------------------------------
F. V. ATLEE
D. M. CULVER* Director July 12, 1994
- ----------------------------------
D. M. CULVER
A. R. DRAGONE* Director July 12, 1994
- ----------------------------------
A. R. DRAGONE
R. HALSTEAD* Director July 12, 1994
- ----------------------------------
R. HALSTEAD
A. J. LEVINE* Director July 12, 1994
- ----------------------------------
A. J. LEVINE
P. W. MACAVOY* Director July 12, 1994
- ----------------------------------
P. W. MACAVOY
V. T. MARCHESI* Director July 12, 1994
- ----------------------------------
V. T. MARCHESI
</TABLE>
II-4
<PAGE> 18
<TABLE>
<CAPTION>
SIGNATURE TITLE DATE
--------- ----- ----
<S> <C> <C>
R. T. RITTER* Controller, July 12, 1994
---------------------------------- (Principal Accounting
R. T. RITTER Officer)
G. J. SELLA, JR.* Director July 12, 1994
----------------------------------
G. J. SELLA, JR.
M. TANENBAUM* Director July 12, 1994
----------------------------------
M. TANENBAUM
A. WEXLER* Director July 12, 1994
----------------------------------
A. WEXLER
*By: T. D. MARTIN
----------------
ATTORNEY-IN-FACT
</TABLE>
II-5
<PAGE> 19
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit No. Description Sequentially Numbered
- ----------- ----------- ---------------------
Page
----
<S> <C>
1.1 Form of Purchase Agreement*
4.1 Form of Indenture between American
Cyanamid Company and The Chase
Manhattan Bank (National
Association) as trustee*
5.1 Opinion of Joseph S. McAuliffe, Esq.,
as to the legality of the securities
being offered*
12.1 Statement of computation of Ratio of
Earnings to Fixed Charges
23.1 Consent of KPMG Peat Marwick
23.2 Consent of Joseph S. McAuliffe, Esq.,
(included in Exhibit 5.1 hereto)*
24.1 Powers of Attorney*
25.1 Form T-1 Statement of Eligibility
of Trustee under the Trust Indenture
Act of 1939 of The Chase Manhattan
Bank (National Association)*
</TABLE>
- -----------------
* Previously filed.
<PAGE> 1
EXHIBIT 12.1
AMERICAN CYANAMID COMPANY
RATIO OF EARNINGS TO FIXED CHARGES
(IN MILLIONS OF DOLLARS, EXCEPT RATIO AMOUNTS)
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31,
----------------------
Three Months
Ended March
1994 1993 1992(1) 1991(1) 1990(1) 1989(1)
--------------- ---- ------ ------ ------ -----
<S> <C> <C> <C> <C> <C> <C>
EARNINGS
--------
Earnings <Loss> from $ 156.2 $(111.8)(2) $555.0 $507.0 $378.0(3) $394.8
continuing
operations before
income taxes
Add:
Fixed Charges 20.5 $ 82.2 $ 77.9 $ 78.4 $114.4 $174.0
Less:
Capitalized
interest (0.7) $ (4.6) $ (4.0) $(11.0) $(13.5) $(14.0)
------- ------- ------ ------ ------ ------
Total Earnings<Loss> $ 176.0 $ (34.2) $628.9 $574.4 $478.9 $554.8
======= ======= ====== ====== ====== ======
FIXED CHARGES
-------------
Interest and debt
expenses $ 16.0 $ 62.4 $ 58.8 $ 53.7 $ 88.4 $147.7
Add:
Capitalized interest 0.7 $ 4.6 $ 4.0 $ 11.0 $ 13.5 $ 14.0
Add:
One-third of rental
expense
3.8 $ 15.2 $ 15.1 $ 13.7 $ 12.5 $ 12.3
------- ------- ------ ------ ------ ------
Total Fixed Charges $ 20.5 $ 82.2 $ 77.9 $ 78.4 $114.4 $174.0
======= ======= ====== ====== ====== ======
RATIO OF EARNINGS TO FIXED
CHARGES 8.59 * 8.07 7.33 4.19(3) 3.19
======= ======= ====== ====== ====== ======
</TABLE>
- ----------------------------------
<PAGE> 2
* Calculation of the ratio results in an amount that is less than one.
The amount of earnings coverage deficiency for the fiscal year ended
December 31, 1993 was $116.4.(2)
(1) Restated for discontinued operations related to the spin-off of Cytec
Industries Inc. in 1993.
(2) Includes one-time, pre-tax charges of $383.6 related to the
acquisition of Immunex Corporation and $207.9 related to a companywide
restructuring program. Excluding these charges, the ratio of earnings
to fixed charges would have been 6.78.
(3) Includes a pre-tax special charge of $97.2 associated primarily with
the curtailment and consolidation of certain product lines. Excluding
this charge, the ratio of earnings to fixed charges would have been
5.04.
<PAGE> 1
EXHIBIT 23.1
ACCOUNTANTS' CONSENT
The Board of Directors
American Cyanamid Company:
We consent to the use of our reports incorporated herein by reference and to
the reference to our Firm under the heading "Experts" in the prospectus. Our
reports refer to the adoption of the provisions of Statements of Financial
Accounting Standards No. 106, "Employers' Accounting for Postretirement
Benefits Other Than Pensions", and No. 109, "Accounting for Income Taxes",
effective January 1, 1993.
KPMG Peat Marwick
Short Hills, New Jersey
July 11, 1994
